N1-acetyl-5-methoxykynuramine (AMK) is produced in the human epidermis and shows antiproliferative effects

Endocrinology

Volumn 156, Issue 5, 2015, Pages 1630-1636

  Kim, Tae Kang ^a   Lin, Zongtao ^a   Li, Wei ^a   Reiter, Russel J ^c   Slominski, Andrzej T ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; N 1 ACETYL 5 METHOXYKYNURAMINE; UNCLASSIFIED DRUG; KYNURAMINE; N-ACETYL-5-METHOXY KYNURENAMINE;

ADULT; AFRICAN AMERICAN; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CAUCASIAN; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DNA SYNTHESIS; EPIDERMIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; KERATINOCYTE; MALE; MELANOCYTE; MELANOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN METABOLISM; SKIN; SKIN PIGMENTATION; AGE; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; MELANOMA; METABOLISM; MIDDLE AGED; SKIN TUMOR; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IN VITRO TECHNIQUES; KERATINOCYTES; KYNURAMINE; MALE; MELANOCYTES; MELANOMA; MELATONIN; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84928997670     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1980     Document Type: Article

References (38)

1. Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29:325-333.
2. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71:2997-3025.
3. Lanoix D, Lacasse AA, Reiter RJ, Vaillancourt C. Melatonin: the watchdog of villous trophoblast homeostasis against hypoxia/reoxygenation- induced oxidative stress and apoptosis. Mol Cell Endocrinol. 2013;381:35-45.
4. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab. 2008;19:17-24.
5. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351:152-166.
6. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101-110.
7. Li DY, Smith DG, Hardeland R, et al. Melatonin receptor genes in vertebrates. Int J Mol Sci. 2013;14:11208-11223.
8. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res. 2009;47:109-126.
9. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol. 2012;212:v, vii, 1-115.
10. Elias PM, Crumrine D, Paller A, Rodriguez-Martin M, Williams ML. Pathogenesis of the cutaneous phenotype in inherited disorders of cholesterol metabolism: therapeutic implications for topical treatment of these disorders. Dermatoendocrinol. 2011;3:100-106.
11. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Rev. 2000;21:457-487.
12. Semak I, Naumova M, Korik E, Terekhovich V, Wortsman J, Slominski A. A novel metabolic pathway of melatonin: oxidation by cytochrome C. Biochemistry. 2005;44:9300-9307.
13. Slominski A, Baker J, Rosano TG, et al. Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture. J Biol Chem. 1996;271:12281-12286.
14. Slominski A, Pisarchik A, Semak I, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J. 2002;16:896-898.
15. Kobayashi H, Kromminga A, Dunlop TW, et al.Arole of melatonin in neuroectodermal-mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors. FASEB J. 2005;19:1710-1712.
16. Slominski A, Pisarchik A, Semak I, Sweatman T, Szczesniewski A, Wortsman J. Serotoninergic system in hamster skin. J Invest Dermatol. 2002;119:934-942.
17. Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniewski A, Wortsman J. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002;511:102-106.
18. Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J. 2006;20:1564-1566.
19. Kim TK, Kleszczynski K, Janjetovic Z, et al. Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells. FASEB J. 2013;27:2742-2755.
20. Kim TK, Lin Z, Tidwell WJ, Li W, Slominski AT. Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro. Mol Cell Endocrinol. 2015;404:1-8.
21. Slominski AT, Kleszczyński K, Semak I, et al. Local melatoninergic system as the protector of skin integrity. Int J Mol Sci. 2014;15: 17705-17732.
22. Fischer TW, Slominski A, Tobin DJ, Paus R. Melatonin and the hair follicle. J Pineal Res. 2008;44:1-15.
23. Kleszczynski K, FischerTW.Melatonin and human skin aging. Dermatoendocrinol. 2012;4:245-252.
24. Janjetovic Z, Nahmias ZP, Hanna S, et al. Melatonin and its metabolites ameliorate ultraviolet B-induced damage in human epidermal keratinocytes. J Pineal Res. 2014;57:90-102.
25. Słominski A, Moellmann G, Kuklinska E, Bomirski A, Pawelek J. Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway, L-tyrosine and L-dopa. J Cell Sci. 1988;89:287-296.
26. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer. 2009;124:1470-1477.
27. Slominski AT, Kim TK, Janjetovic Z, et al. 20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells.AmJ Physiol Cell Physiol. 2011;300:C526-C541.
28. Slominski AT, Janjetovic Z, Kim TK, et al. Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes. Anticancer Res. 2012;32:3733-3742.
29. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2012;25:14-27.
30. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155-1228.
31. Slominski A, Kim TK, Brozyna AA, et al. The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. Arch Biochem Biophys. 2014;563:79-93.
32. Slominski A, Chassalevris N, Mazurkiewicz J, Maurer M, Paus R. Murine skin as a target for melatonin bioregulation. Exp Dermatol. 1994;3:45-50.
33. Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res. 1993;206:189-194.
34. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/ melatoninergic system: securing a place under the sun. FASEB J. 2005;19:176-194.
35. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res. 2013;54:245-257.
36. Reiter RJ, Tan DX, Galano A. Melatonin reduces lipid peroxidation and membrane viscosity. Front Physiol. 2014;5:377.
37. Kleszczyński K, Tukaj S, Kruse N, Zillikens D, Fischer TW. Melatonin prevents ultraviolet radiation-induced alterations in plasma membrane potential and intracellular pH in human keratinocytes. J Pineal Res. 2013;54:89-99.
38. Fischer TW, Kleszczyński K, Hardkop LH, Kruse N, Zillikens D. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2'-deoxyguanosine) in ex vivo human skin. J Pineal Res. 2013;54:303-312.